



**VIJAYA
DIAGNOSTIC
CENTRE**

February 13, 2023

To,
Listing Department
National Stock Exchange Of India Limited,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
NSE Symbol. VIJAYA

To,
The Corporate Relations Department
BSE Limited,
Phiroz Jeejeebhoy Towers,
25th floor, Dalal Street,
Mumbai - 400 001
BSE Scrip Code. 543350

Dear Sir/Madam

Subject: Intimation of Press Release.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the "Press Release" being issued by the Company.

Please take the information on record

Thanking You.

Yours Faithfully
For **Vijaya Diagnostic Centre Limited**

**SUPRITA
SURA REDDY**

**S Suprita Reddy
Chief Executive Officer**

Digitally signed by SUPRITA SURA REDDY
DN: c=IN, o=PERSONAL, title=9913,
pseudonym=56fe28a97d9943a183577de997c5a0
d6,
2.5.4.20=aa258bcdeddad165e7d7b0d2e49b6e12
df4fc34973ad0ca3aaf2080f04ec376,
postalCode=500033, st=Telangana,
serialNumber=315074dfa1901f6701923f5b5a0f21
550b5e59ba771f420f4c8e9a31d3d3589e,
cn=SUPRITA SURA REDDY
Date: 2023.02.13 15:03:34 +05'30'

Encl.: As above



**VIJAYA
DIAGNOSTIC
CENTRE**

Regd. Office - 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.

Vijaya Diagnostic Centre Ltd. announces Q3 FY23 Results
Non-Covid Revenues grew by 9.8% Y-o-Y to Rs. 1,122 Mn
Wellness share in Q3FY23 up at 12.9% as against 8.5% in Q3FY22

Hyderabad, February 13, 2023: Vijaya Diagnostic Centre Limited (NSE: VIJAYA, BSE: 543350), one of India's leading integrated diagnostic chain, has announced its financial results for the quarter and nine months ended 31st December 2022.

Consolidated Financial Performance:

Particulars (Rs. Mn)	Q3FY23	Q3FY22	YoY	9MFY23	9MFY22	YoY
Revenue from Operations	1,131	1,108	2.1%	3,382	3,462	-2.3%
EBITDA	443	478	-7.4%	1,329	1,558	-14.7%
EBITDA Margin (%)	39.1%	43.2%	-410 bps	39.3%	45.0%	-570 bps
Profit after Tax	164	253	-35.3%	571	860	-33.5%

Performance Highlights Q3FY23 vs. Q3FY22:

- Revenue from Operations increased by 2.1% YoY to Rs. 1,131 Mn, Non-Covid Revenues grew by 9.8% YoY
 - During Q3FY23, the Non-COVID business comprised 99% of total revenue share as against 92% revenue share in Q3FY22
 - Wellness share in Q3FY23 was up at 12.9% as against 8.5% in Q3FY22
 - Revenue composition from B2C segment stood at 95%
- EBITDA stood at Rs. 443 Mn. EBITDA margin for the quarter was 39.1%
 - Healthy non covid revenue coupled with operating leverage assisted margin performance despite costs on account of new centres
- PAT stood at Rs. 164 Mn. translating into a PAT margin of 14.5%

Performance Highlights 9MFY23 vs. 9MFY22:

- Revenue from Operations decreased by 2.3% YoY to Rs. 3,382 Mn, Non-Covid Revenues grew by 12.2% YoY
 - Wellness share in 9MFY23 was up at 11.7% as against 6.3% in 9MFY22
 - Revenue composition from B2C segment continued to stay strong at 95%
- EBITDA stood at Rs. 1,329 Mn. EBITDA margin was 39.3%
- PAT stood at Rs. 571 Mn. translating into a PAT margin of 16.9%

Commenting on the performance Ms. Suprita Reddy, CEO said, *“We are pleased to report steady performance during a seasonally soft quarter for the industry. The volume trends that were slow in the months of October and November, saw a significant improvement in December and we hope to carry this momentum into the upcoming quarter.*

Our ongoing efforts to expand the network through the addition of new hubs and spokes has been progressing well. During this quarter, we opened 5 centers including a one-of-its-kind facility at Punjagutta. Our newly opened state-of-the-art facilities in Punjagutta and Rajahmundry have received an overwhelmingly positive response from our customers. Additionally, our efforts to improve digital operations are proceeding smoothly, and we anticipate that these initiatives will considerably improve operational efficiency and enhance customer experience across all of our centers.

Looking ahead, the outlook for the diagnostics industry remains positive, with increasing demand for advanced medical services and a growing emphasis on preventive healthcare. We remain confident that our integrated diagnostics offerings, well-established brand and our robust B2C network will enable us to capitalize on the huge market opportunity.”

-END-

About Us:

Vijaya Diagnostic Centre Limited (VDCL), is the largest integrated diagnostic chain having dominant presence in Southern India. Vijaya provides one-stop solution for pathology and radiology testing services to customers through extensive operational network, which consists of 117 diagnostic centres and 16 reference laboratories across 19 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata. The Company offers comprehensive range of diagnostic services from Basic pathology to high-end radiology.

Corporate Identification No: L85195TG2002PLC039075

Regd. Office: 6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.

For more information, please visit www.vijayadiagnostic.com OR contact:

Mr. Siva Rama Raju

Head of Strategy

Vijaya Diagnostic Centre Limited

Tel: +91 99485 95555 / +91 90597 00749

Email: sivaramaraju.v@vijayadiagnostic.in
ir@vijayadiagnostic.in

Anoop Poojari / Devrishi Singh

Investor Relations Advisors

CDR India

Tel: +91 98330 90434 / +91 98205 30918

Email: anoop@cdr-india.com
devrishi@cdr-india.com

DISCLAIMER:

Certain statements that may be made in the press release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, import duties, litigation, labour relations etc. Actual results might differ substantially from those expressed or implied. Vijaya Diagnostic Centre Limited will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.